Patents by Inventor Baoqing Gong

Baoqing Gong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Aryl triazines as LPAAT-? inhibitors and uses thereof
    Patent number: 7618968
    Abstract: The invention relates to aryl triazines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase ? (LPAAT-?) activity and/or proliferation of cells such as tumor cells.
    Type: Grant
    Filed: August 6, 2007
    Date of Patent: November 17, 2009
    Assignee: Cell Therapeutics, Inc.
    Inventors: Rama Bhatt, Baoqing Gong, Feng Hong, Scott A Jenkins, J Peter Klein, Anil M Kumar, John Tulinsky
  • LPAAT-? inhibitors and uses thereof
    Patent number: 7608620
    Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase ? (LPAAT-?) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-? activity.
    Type: Grant
    Filed: November 16, 2006
    Date of Patent: October 27, 2009
    Assignee: Cell Therapeutics, Inc.
    Inventors: Lynn Bonham, Baoqing Gong, Robert E Finney, David M Hollenback, J Peter Klein, David W Leung, Scott A Shaffer, Norina M Tang, John Tulinsky, Thayer H White
  • PYRIMIDINES AND USES THEREOF
    Publication number: 20090099183
    Abstract: The invention relates to pyrimidines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase ? (LPAAT-?) activity and/or proliferation of cells such as tumor-cells.
    Type: Application
    Filed: August 19, 2008
    Publication date: April 16, 2009
    Applicant: Cell Therapeutics, Inc.
    Inventors: Rama BHATT, Baoqing GONG, Feng HONG, Scott A. JENKINS, J. Peter KLEIN, Cory T. KOHM, John TULINSKY
  • Pyrimidines and uses thereof
    Patent number: 7419984
    Abstract: The invention relates to pyrimidines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase ? (LPAAT-?) activity and/or proliferation of cells such as tumor-cells.
    Type: Grant
    Filed: September 24, 2003
    Date of Patent: September 2, 2008
    Assignee: Cell Therapeutics, Inc.
    Inventors: Rama Bhatt, Baoqing Gong, Feng Hong, Scott A Jenkins, J Peter Klein, Cory T Kohm, John Tulinsky
  • Aryl triazines as LPAAT-beta inhibitors and uses thereof
    Publication number: 20080064700
    Abstract: The invention relates to aryl triazines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase ? (LPAAT-?) activity and/or proliferation of cells such as tumor cells.
    Type: Application
    Filed: August 6, 2007
    Publication date: March 13, 2008
    Applicant: Cell Therapeutics, Inc.
    Inventors: Rama Bhatt, Baoqing Gong, Feng Hong, Scott Jenkins, J. Klein, Anil Kumar, John Tulinsky
  • Aryl triazines as LPAAT-? inhibitors and uses thereof
    Patent number: 7291616
    Abstract: The invention relates to aryl triazines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase ? (LPAAT-?) activity and/or proliferation of cells such as tumor cells.
    Type: Grant
    Filed: October 30, 2002
    Date of Patent: November 6, 2007
    Assignee: Cell Therapeutics, Inc.
    Inventors: Rama Bhatt, Baoqing Gong, Feng Hong, Scott A. Jenkins, J. Peter Klein, Anil M. Kumar, John Tulinsky
  • Uses of tricyclic compounds
    Patent number: 7247630
    Abstract: Novel tricyclic compounds are disclosed having the general structure of Formulas I or II: were R1, R2 and R3 are defined in the written description of the invention. The compounds are useful for the treatment or prevention of symptoms or manifestations associated with diseases or disorders affected by intracellular cytokine signaling.
    Type: Grant
    Filed: January 24, 2003
    Date of Patent: July 24, 2007
    Assignee: Cell Therapeutics, Inc.
    Inventors: Baoqing Gong, J. Peter Klein, Michael Coon
  • LPAAT-? inhibitors and uses thereof
    Patent number: 7199238
    Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase ? (LPAAT-?) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-? activity.
    Type: Grant
    Filed: September 12, 2005
    Date of Patent: April 3, 2007
    Assignee: Cell Therapuetics, Inc.
    Inventors: Lynn Bonham, Baoqing Gong, Robert E Finney, David M Hollenback, J. Peter Klein, David W Leung, Scott A Shaffer, Norina M Tang, John Tulinsky, Thayer H White
  • LPAAT-beta inhibitors and uses thereof
    Publication number: 20070072856
    Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase ? (LPAAT-?) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-? activity.
    Type: Application
    Filed: November 16, 2006
    Publication date: March 29, 2007
    Applicant: Cell Therapeutics, Inc.
    Inventors: Baoqing Gong, John Tulinsky, Lynn Bonham, J. Klein, Robert Finney, David Hollenback, Scott Shaffer, Norina Tang, Thayer White, David Leung
  • LPAAT-? inhibitors and uses thereof
    Patent number: 7064125
    Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase ? (LPAAT-?) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-? activity.
    Type: Grant
    Filed: November 13, 2003
    Date of Patent: June 20, 2006
    Assignee: Cell Therapeutics, Inc.
    Inventors: Baoqing Gong, John Tulinsky, Lynn Bonham, J. Peter Klein, Robert E. Finney, David M. Hollenback, Scott A. Shaffer, Norina M. Tang, Thayer H. White, David W. Leung
  • LPAAT-beta inhibitors and uses thereof
    Publication number: 20060035896
    Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase ? (LPMT-?) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-? activity.
    Type: Application
    Filed: September 12, 2005
    Publication date: February 16, 2006
    Applicant: Cell Therapeutics, Inc.
    Inventors: Lynn Bonham, J. Klein, Robert Finney, David Hollenback, Scott Shaffer, Norina Tang, Thayer White, David Leung, Baoqing Gong, John Tulinsky
  • Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
    Patent number: 6878715
    Abstract: Novel heterocyclic compounds having a six membered ring structure fused to a five membered ring structure are found to be useful for the treatment and prevention of symptoms or manifestations associated with disorders affected by Interleukin-12 (“IL-12”) intracellular signaling, such as, for example, Th1 cell-mediated disorders. The therapeutic compounds, pharmaceutically acceptable derivatives (e.g., resolved enantiomers, diastereomers, tautomers, salts and solvates thereof) or prodrugs thereof, have the following general formula: Each X, Y and Z are independently selected from a member of the group consisting of C(R3), N, N(R3) and S.
    Type: Grant
    Filed: April 7, 2000
    Date of Patent: April 12, 2005
    Assignee: Cell Therapeutics, Inc.
    Inventors: J. Peter Klein, Stephen J. Klaus, Anil M. Kumar, Baoqing Gong
  • Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same
    Publication number: 20050049262
    Abstract: Novel heterocyclic compounds having a six membered ring structure fused to a five membered ring structure are found to be useful for the treatment and prevention of symptoms or manifestations associated with disorders affected by lnterleukin-12 (“IL-12”) intracellular signaling, such as, for example, Th1 cell-mediated disorders. The therapeutic compounds, pharmaceutically acceptable derivatives (e.g., resolved enantiomers, diastereomers, tautomers, salts and solvates thereof) or prodrugs thereof, have the following general formula: Each X, Y and Z are independently selected from a member of the group consisting of C(R3), N, N(R3) and S.
    Type: Application
    Filed: August 16, 2004
    Publication date: March 3, 2005
    Applicant: Cell Therapeutics, Inc.
    Inventors: J. Klein, Stephen Klaus, Anil Kumar, Baoqing Gong
  • Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same
    Publication number: 20050032748
    Abstract: Novel heterocyclic compounds having a six membered ring structure fused to a five membered ring structure are found to be useful for the treatment and prevention of symptoms or manifestations associated with disorders affected by Interleukin-12 (“IL-12”) intracellular signaling, such as, for example, Th1 cell-mediated disorders. The therapeutic compounds, pharmaceutically acceptable derivatives (e.g., resolved enantiomers, diastereomers, tautomers, salts and solvates thereof) or prodrugs thereof, have the following general formula: Each X, Y and Z are independently selected from a member of the group consisting of C(R3), N,N(R3) and S.
    Type: Application
    Filed: August 3, 2004
    Publication date: February 10, 2005
    Applicant: Cell Therapeutics, Inc.
    Inventors: J. Klein, Stephen Klaus, Anil Kumar, Baoqing Gong
  • Pyrimidines and uses thereof
    Publication number: 20040204386
    Abstract: The invention relates to pyrimidines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase &bgr; (LPAAT-&bgr;) activity and/or proliferation of cells such as tumor-cells.
    Type: Application
    Filed: September 24, 2003
    Publication date: October 14, 2004
    Applicant: Cell Therapeutics, Inc.
    Inventors: Rama Bhatt, Baoqing Gong, Feng Hong, Scott A. Jenkins, J. Peter Klein, Cory T. Kohm, John Tulinsky
  • LPAAT-beta inhibitors and uses thereof
    Publication number: 20040162288
    Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase &bgr; (LPAAT-&bgr;) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-&bgr; activity.
    Type: Application
    Filed: November 13, 2003
    Publication date: August 19, 2004
    Applicant: Cell Therapeutics, Inc.
    Inventors: Baoqing Gong, John Tulinsky, Lynn Bonham, J. Peter Klein, Robert E. Finney, David M. Hollenback, Scott A. Shaffer, Norina M. Tang, Thayer H. White, David W. Leung
  • Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same
    Patent number: 6774130
    Abstract: Novel heterocyclic compounds having a six membered ring structure fused to a five membered ring structure are found to be useful for the treatment and prevention of symptoms or manifestations associated with disorders affected by Interleukin-12 (“IL-12”) intracellular signaling, such as, for example, Th1 cell-mediated disorders. The therapeutic compounds, pharmaceutically acceptable derivatives (e.g., resolved enantiomers, diastereomers, tautomers, salts and solvates thereof) or prodrugs thereof, have the following general formula: Each X, Y and Z are independently selected from a member of the group consisting of C(R3), N, N(R3) and S.
    Type: Grant
    Filed: April 9, 1999
    Date of Patent: August 10, 2004
    Assignee: Cell Therapeutics, Inc.
    Inventors: J. Peter Klein, Stephen J. Klaus, Anil M. Kumar, Baoqing Gong
  • Tricyclic compounds and their uses
    Publication number: 20030162801
    Abstract: Novel tricyclic compounds are found to be useful for the treatment or prevention of symptoms or manifestations associated with diseases or disorders affected by cytokine intracellular signaling.
    Type: Application
    Filed: January 24, 2003
    Publication date: August 28, 2003
    Inventors: Baoqing Gong, J. Peter Klein, Michael Coon
  • Aryl triazines as LPAAT-SS inhibitors and uses thereof
    Publication number: 20030153570
    Abstract: The invention relates to aryl triazines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase &bgr; (LPAAT-&bgr;) activity and/or proliferation of cells such as tumor cells.
    Type: Application
    Filed: October 30, 2002
    Publication date: August 14, 2003
    Applicant: Cell Therapeutics, Inc.
    Inventors: Rama Bhatt, Baoqing Gong, Feng Hong, Scott A. Jenkins, J. Peter Klein, Anil M. Kumar, John Tulinsky
  • Tricyclic fused xanthine compounds and their uses
    Patent number: 6586429
    Abstract: Novel tricyclic compounds are found to be useful for the treatment or prevention of symptoms or manifestations associated with diseases or disorders affected by cytokine intracellular signaling. The compounds have the following formulas where R1, R2 and R3 are defined in the written description of the invention.
    Type: Grant
    Filed: November 29, 2000
    Date of Patent: July 1, 2003
    Assignee: Cell Therapeutics, Inc.
    Inventors: Baoqing Gong, J. Peter Klein, Michael Coon